Key result
Intravenous rilmenidine inhibited the RSNA baroreflex range by 33%, an effect reversed by idazoxan and 2-MI, indicating mediation via imidazoline receptors and alpha2-adrenoceptors in the RVLM.
The hypotensive and sympatho-inhibitory actions of systemic rilmenidine are primarily mediated via imidazoline receptors and alpha2-adrenoceptors in the rostral ventrolateral medulla.
Answers are grounded in this paper and cite their sources.
Rilmenidine's RVLM-mediated sympathoinhibition is hypothesis-generating; leaves open translation to human hypertension and receptor-selective therapies.
OBJECTIVES: To determine whether the hypotensive and sympathetic baroreflex inhibition by rilmenidine administered systemically are mediated via imidazoline receptors in the rostral ventrolateral medulla (RVLM). METHODS: Initial dose-response curves to rilmenidine were determined in urethane anaesthetized rabbits. Effects of a single intravenous dose of rilmenidine (445 microg/kg) on the renal sympathetic nerve activity (RSNA) baroreflex were examined before and after microinjection into the RVLM of the mixed imidazoline/alpha2-adrenoceptor antagonist idazoxan and the alpha2-adrenoceptor antagonist 2-methoxyidazoxan (2-MI). RESULTS: Intravenous administration of rilmenidine lowered mean arterial pressure and RSNA, inhibited the RSNA baroreflex range by 33% and shifted the baroreflex curve to the left. Idazoxan injected into the RVLM reversed the hypotension and completely restored the baroreflex curve at doses that did not affect the hypotension produced by the selective alpha2-adrenoceptor agonist alpha-methylnoradrenaline. The alpha2-adrenoceptor antagonist, 2-MI also reversed the rilmenidine sympatho-inhibition suggesting that alpha2-adrenoceptors are activated as well. CONCLUSIONS: The results of the present study show that the hypotensive and sympatho-inhibitory actions of systemic rilmenidine are primarily mediated via imidazoline receptors in the RVLM. However, alpha2-adrenoceptors are also involved, probably as a direct result of the imidazoline receptor action.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2006) studied this question. Rilmenidine vs. Baseline (before microinjection) was evaluated on Renal sympathetic nerve activity (RSNA) baroreflex range. Intravenous rilmenidine inhibited the RSNA baroreflex range by 33%, an effect reversed by idazoxan and 2-MI, indicating mediation via imidazoline receptors and alpha2-adrenoceptors in the RVLM.
Synapse has enriched 10 related papers. Consider them for comparative context: